CJC-1295 with DAC
Analytical Standards & Laboratory Handling
Verified laboratory protocols, reconstitution parameters, and handling guidelines.
Pharmacological Profile & Mechanism of Action
What it is: CJC-1295 with DAC is a synthetic GHRH analogue conjugated to a Drug Affinity Complex (DAC) that binds irreversibly to circulating serum albumin, extending its biological half-life to 6–8 days.
How it works: By binding to blood albumin, CJC-1295 with DAC provides continuous, 24/7 stimulation of the pituitary GHRH receptor. This drives a sustained, around-the-clock elevation in baseline growth hormone and circulating IGF-1 levels from a single weekly or bi-weekly dose.
Why researchers study it: Researched for long-acting growth hormone elevation, continuous tissue healing, sustained muscle preservation, and anti-catabolic support without requiring daily injections.
Compound & Molecular Specifications
Certificate of Analysis StandardsFrequently Stacked with CJC-1295 No DAC (Mod GRF 1-29)
Clinically verified combinations activating complementary physiological pathways without receptor competition.
Ipamorelin (GHRP Selective)
CJC-1295 (GHRH agonist) stimulates the synthesis and transcription of Growth Hormone in pituitary somatotropes, while Ipamorelin (selective GHSR agonist) suppresses somatostatin and triggers the vesicular release pulse. Together they produce an amplified physiological GH pulse up to 5x higher than either alone.
